Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $260.50 Average PT from Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have received a consensus recommendation of “Buy” from the eleven research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $263.8750.

Several brokerages have issued reports on KRYS. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday, December 29th. Bank of America increased their target price on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a report on Friday, October 17th. Cowen reiterated a “buy” rating on shares of Krystal Biotech in a research report on Friday. HC Wainwright restated a “buy” rating and set a $310.00 price target (up from $240.00) on shares of Krystal Biotech in a research report on Friday. Finally, Citigroup raised their price objective on Krystal Biotech from $320.00 to $336.00 and gave the company a “buy” rating in a research note on Monday.

Krystal Biotech Stock Up 7.3%

KRYS opened at $291.93 on Friday. The business’s fifty day simple moving average is $230.81 and its 200 day simple moving average is $184.90. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $292.89. The stock has a market cap of $8.47 billion, a PE ratio of 43.77 and a beta of 0.46.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $1.54. The firm had revenue of $97.80 million during the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. As a group, equities analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the transaction, the insider directly owned 1,413,711 shares in the company, valued at $311,242,613.76. This trade represents a 1.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 13.70% of the stock is currently owned by insiders.

Institutional Trading of Krystal Biotech

A number of institutional investors have recently made changes to their positions in KRYS. Avoro Capital Advisors LLC boosted its position in Krystal Biotech by 4.4% during the 3rd quarter. Avoro Capital Advisors LLC now owns 2,777,777 shares of the company’s stock valued at $490,361,000 after buying an additional 117,777 shares during the period. State Street Corp raised its stake in shares of Krystal Biotech by 10.5% during the second quarter. State Street Corp now owns 1,355,346 shares of the company’s stock valued at $186,306,000 after acquiring an additional 128,639 shares during the last quarter. Soleus Capital Management L.P. boosted its holdings in shares of Krystal Biotech by 108.9% during the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after purchasing an additional 481,200 shares during the period. Braidwell LP grew its stake in shares of Krystal Biotech by 81.6% in the second quarter. Braidwell LP now owns 727,811 shares of the company’s stock worth $100,045,000 after purchasing an additional 327,067 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Krystal Biotech by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 619,547 shares of the company’s stock valued at $85,174,000 after purchasing an additional 7,194 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.